KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Safety and durability of influenza and SARS-CoV-2 antibody responses through 6 months after a single dose of mRNA-1083, a multicomponent influenza and COVID-19 vaccine, in adults ≥50 years.

Lusine Kostanyan, Iris Wu, Melissa Sinkiewicz, Jose Cardona, Kimball Johnson, Rituparna Das

Hum Vaccin Immunother 22(1) 2675021

PMID42213900
PMCIDPMC13224755
DOI10.1080/21645515.2026.2675021
发表日期2026-05-29
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

Seasonal influenza and SARS-CoV-2 continue to contribute substantially to global morbidity and mortality. mRNA-1083 is an investigational multicomponent mRNA vaccine targeting seasonal influenza and SARS-CoV-2. In this phase 3, observer-blind, active-controlled trial (NCT06097273), adults (aged ≥50 y) were randomly assigned (1:1) to receive mRNA-1083 (40 µg; plus placebo) or age-appropriate licensed comparator vaccines for influenza and COVID-19. Two substudies were included: Cohort A (≥65 y) and Cohort B (50-64 y). Primary objectives were to demonstrate noninferiority of mRNA-1083 versus comparators for influenza hemagglutination inhibition (HAI) responses and SARS-CoV-2 neutralizing antibody (nAb; PsVNA) responses at Day 29 after vaccination and to evaluate safety and reactogenicity of study vaccines. Here, we report safety, reactogenicity, and immunogenicity of mRNA-1083 through Day 181 in adults aged ≥50 y. mRNA-1083 induced HAI titers against all vaccine-matched influenza strains that were maintained through 6 months and were generally comparable to, or higher than, comparator responses. SARS-CoV-2 nAb responses remained higher for mRNA-1083 than comparators through 6 months. Reactogenicity was predominantly grade 1-2 in severity, and vaccination-related unsolicited adverse events were similar between groups. No serious adverse events or deaths related to vaccination were reported through 6 months. In adults aged ≥50 y, mRNA-1083 elicited durable influenza and SARS-CoV-2 humoral immune responses with an acceptable safety profile through 6 months. These findings support the use of mRNA-1083 as a multicomponent vaccine.ClinicalTrials.gov identifier: NCT06097273 (https://clinicaltrials.gov/study/NCT06097273).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。